Colorectal Cancer (MSK, Cancer Discovery 2022)

Summary

Colorectal Cancer (MSK, Cancer Discovery 2022) is a study catalogued by cBioPortal DataHub under the cancer-type code coadread. EvidenceHelix groups it with colorectal studies.

Study description

Targeted sequencing of patient-derived xenografts, cell lines, tumors and their matched normals from 22 colorectal samples via MSK-IMPACT.

Text as published in the source's study metadata.

Citation & PubMed

Yaeger et al. Cancer Discovery 2022

Linked PubMed records: PMID 36355783

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

coadread_mskresistance_2022

Short name

COADREAD (MSK, 2022)

Source cancer-type code

coadread

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Yaeger et al. Cancer Discovery 2022

• PubMed record 36355783 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Colorectal Adenocarcinoma Triplets (MSK, Genome Biol 2014)

  Targeted sequencing of primary, metastatic, and normal tissues from 69 colorectal adenocarcinoma patients.

  ColorectalMSK studiesSource code coadreadPubMed 1

• Colorectal Cancer (HTAN MSK, Nature 2025)

  Targeted genomic and single-cell RNA sequencing of normal colon, primary colorectal cancer, and matched metastatic samples from 29 patients.

  ColorectalMSK studiesSource code coadreadPubMed 1

• Colorectal Cancer (MSK, Gastroenterology 2020)

  Targeted sequencing of 471 unresectable colorectal tumor/normal pairs via MSK-IMPACT.

  ColorectalMSK studiesSource code coadreadPubMed 1

• Colorectal Cancer (MSK, JCO Precis Oncol 2022)

  Molecular characterization of 47 BRAF inhibitor-naive colorectal cancer patients with dual RAS hotspot/BRAF V600E mutations.

  ColorectalMSK studiesSource code coadreadPubMed 1

• Disparities in metastatic colorectal cancer between Africans and Americans (MSK, 2020)

  Targeted sequencing of 64 colorectal tumor/normal pairs via MSK-IMPACT to determine the epigenetic differences seen in Nigerian patients.

  ColorectalMSK studiesSource code coadreadPubMed 1

• Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)

  Targeted sequencing of 1134 metastatic colorectal tumor/normal pairs.

  ColorectalMSK studiesSource code coadreadPubMed 1

• Rectal Cancer (MSK,Nature Medicine 2019)

  MSK-IMPACT targeted sequencing of matched rectal cancer tumor and tumoroid samples.

  ColorectalMSK studiesSource code coadreadPubMed 1

• Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)

  Whole-exome sequencing of 619 colorectal cancers with clinicopathologic annotations.

  ColorectalOther published and consortium studiesSource code coadreadPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.